GeneOne Life Science, Inc. (011000.KS)
KRW 2035.0
(-3.1%)
KRW 2035.0
(-3.1%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -48.36 Billion KRW | -20.68% |
| 2022 | -40.07 Billion KRW | -45.71% |
| 2021 | -27.5 Billion KRW | -49.01% |
| 2020 | -18.45 Billion KRW | -124.86% |
| 2019 | -8.2 Billion KRW | 27.09% |
| 2018 | -11.25 Billion KRW | 54.71% |
| 2017 | -24.86 Billion KRW | -77.65% |
| 2016 | -13.99 Billion KRW | -285.84% |
| 2015 | -3.62 Billion KRW | 43.57% |
| 2014 | -6.42 Billion KRW | -1.86% |
| 2013 | -6.3 Billion KRW | 24.85% |
| 2012 | -8.39 Billion KRW | -76.93% |
| 2011 | -4.74 Billion KRW | -169.64% |
| 2010 | -1.76 Billion KRW | 76.37% |
| 2009 | -7.44 Billion KRW | -42.02% |
| 2008 | -5.24 Billion KRW | -6.17% |
| 2007 | -4.93 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -11.09 Billion KRW | 1.56% |
| 2024 Q2 | -11.69 Billion KRW | -5.35% |
| 2023 FY | -48.36 Billion KRW | -20.68% |
| 2023 Q1 | -13.17 Billion KRW | 21.06% |
| 2023 Q2 | -12.09 Billion KRW | 8.22% |
| 2023 Q3 | -11.82 Billion KRW | 2.18% |
| 2023 Q4 | -11.27 Billion KRW | 4.66% |
| 2022 Q2 | -9.39 Billion KRW | -38.6% |
| 2022 Q3 | -7.22 Billion KRW | 23.09% |
| 2022 FY | -40.07 Billion KRW | -45.71% |
| 2022 Q4 | -16.68 Billion KRW | -131.03% |
| 2022 Q1 | -6.77 Billion KRW | 29.39% |
| 2021 Q1 | -3.17 Billion KRW | 58.31% |
| 2021 FY | -27.5 Billion KRW | -49.01% |
| 2021 Q4 | -9.59 Billion KRW | -12.18% |
| 2021 Q2 | -6.19 Billion KRW | -95.17% |
| 2021 Q3 | -8.55 Billion KRW | -38.14% |
| 2020 Q4 | -7.61 Billion KRW | -112.3% |
| 2020 FY | -18.45 Billion KRW | -124.86% |
| 2020 Q3 | -3.58 Billion KRW | 17.62% |
| 2020 Q2 | -4.35 Billion KRW | -49.51% |
| 2020 Q1 | -2.91 Billion KRW | -60.77% |
| 2019 FY | -8.2 Billion KRW | 27.09% |
| 2019 Q1 | -2.18 Billion KRW | 28.15% |
| 2019 Q2 | -3.7 Billion KRW | -69.59% |
| 2019 Q3 | -513.12 Million KRW | 86.14% |
| 2019 Q4 | -1.81 Billion KRW | -252.84% |
| 2018 Q3 | -1.41 Billion KRW | 59.45% |
| 2018 Q4 | -3.03 Billion KRW | -115.42% |
| 2018 Q2 | -3.47 Billion KRW | -4.42% |
| 2018 Q1 | -3.33 Billion KRW | 63.41% |
| 2018 FY | -11.25 Billion KRW | 54.71% |
| 2017 Q1 | -4.27 Billion KRW | -6.99% |
| 2017 Q3 | -3.81 Billion KRW | 50.14% |
| 2017 Q4 | -9.1 Billion KRW | -138.42% |
| 2017 FY | -24.86 Billion KRW | -77.65% |
| 2017 Q2 | -7.65 Billion KRW | -79.01% |
| 2016 Q4 | -3.99 Billion KRW | -7.69% |
| 2016 FY | -13.99 Billion KRW | -285.84% |
| 2016 Q3 | -3.71 Billion KRW | 26.74% |
| 2016 Q2 | -5.06 Billion KRW | -318.27% |
| 2016 Q1 | -1.21 Billion KRW | 21.58% |
| 2015 Q1 | -930.62 Million KRW | 75.8% |
| 2015 Q3 | -93.27 Million KRW | 91.18% |
| 2015 FY | -3.62 Billion KRW | 43.57% |
| 2015 Q4 | -1.54 Billion KRW | -1556.95% |
| 2015 Q2 | -1.05 Billion KRW | -13.64% |
| 2014 Q4 | -3.84 Billion KRW | -249.29% |
| 2014 FY | -6.42 Billion KRW | -1.86% |
| 2014 Q3 | -1.1 Billion KRW | -2.52% |
| 2014 Q2 | -1.07 Billion KRW | -164.81% |
| 2014 Q1 | -405.62 Million KRW | -14.12% |
| 2013 Q2 | -2.65 Billion KRW | -41.97% |
| 2013 Q1 | -1.87 Billion KRW | 34.98% |
| 2013 Q3 | -1.42 Billion KRW | 46.57% |
| 2013 Q4 | -355.42 Million KRW | 74.99% |
| 2013 FY | -6.3 Billion KRW | 24.85% |
| 2012 FY | -8.39 Billion KRW | -76.93% |
| 2012 Q2 | -2.28 Billion KRW | -101.76% |
| 2012 Q3 | -931.75 Million KRW | 59.21% |
| 2012 Q4 | -2.88 Billion KRW | -209.23% |
| 2012 Q1 | -1.13 Billion KRW | 0.0% |
| 2011 Q3 | -254.98 Million KRW | 79.47% |
| 2011 FY | -4.74 Billion KRW | -169.64% |
| 2011 Q2 | -1.24 Billion KRW | -154.51% |
| 2011 Q1 | -487.92 Million KRW | 0.0% |
| 2011 Q4 | - KRW | 100.0% |
| 2010 FY | -1.76 Billion KRW | 76.37% |
| 2010 Q3 | -600.2 Million KRW | 6.05% |
| 2010 Q2 | -638.86 Million KRW | 30.74% |
| 2010 Q1 | -922.35 Million KRW | 0.0% |
| 2010 Q4 | - KRW | 100.0% |
| 2009 Q2 | -809.1 Million KRW | 6.25% |
| 2009 Q3 | -1.02 Billion KRW | -26.64% |
| 2009 Q4 | - KRW | 100.0% |
| 2009 FY | -7.44 Billion KRW | -42.02% |
| 2009 Q1 | -863.04 Million KRW | 31.82% |
| 2008 Q3 | -1.2 Billion KRW | 14.75% |
| 2008 Q4 | -1.26 Billion KRW | -5.12% |
| 2008 FY | -5.24 Billion KRW | -6.17% |
| 2008 Q2 | -1.41 Billion KRW | -3.72% |
| 2008 Q1 | -1.36 Billion KRW | -0.44% |
| 2007 Q4 | -1.35 Billion KRW | -5.71% |
| 2007 Q2 | -1.47 Billion KRW | -79.05% |
| 2007 Q3 | -1.28 Billion KRW | 13.23% |
| 2007 Q1 | -825.62 Million KRW | 0.0% |
| 2007 FY | -4.93 Billion KRW | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| ORIENT BIO Inc. | 1.45 Billion KRW | 3429.274% |
| Green Cross Holdings Corporation | -16.43 Billion KRW | -194.247% |
| Green Cross Holdings Corporation | 34.43 Billion KRW | 240.457% |
| Pharmicell Co., Ltd. | 950.99 Million KRW | 5186.037% |
| Green Cross Corporation | 34.43 Billion KRW | 240.457% |
| Celltrion, Inc. | 651.43 Billion KRW | 107.425% |
| Samsung Biologics Co.,Ltd. | 1155.98 Billion KRW | 104.184% |
| SK bioscience Co.,Ltd. | -4.73 Billion KRW | -922.366% |
| SK Biopharmaceuticals Co., Ltd. | -37.52 Billion KRW | -28.905% |
| Prestige BioPharma Limited | -62.78 Billion KRW | 22.96% |